(Q47220999)

English

Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts

scientific article published in July 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts (English)

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

object named as

Kuniaki Shirao

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

author name string

Tetsuya Hamaguchi

1

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

Yasuhiro Matsumura

2

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

Yukihiro Nakanishi

3

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

Kei Muro

4

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

Yasuhide Yamada

5

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

Yasuhiro Shimada

6

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

Hisae Niki

8

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

Saiko Hosokawa

9

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

Toshiaki Tagawa

10

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

Tadao Kakizoe

11

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

publication date

1 July 2004

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

95

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

7

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

608-613

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02495.X

21 January 2018

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02495.X

21 January 2018

Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02495.X

21 January 2018

Characteristics of human tumour xenografts transplanted under the renal capsule of immunocompetent mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02495.X

21 January 2018

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02495.X

21 January 2018

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02495.X

21 January 2018

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02495.X

21 January 2018

Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02495.X

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02495.X

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02495.X

21 January 2018

Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02495.X

21 January 2018

Identifiers

10.1111/J.1349-7006.2004.TB02495.X

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

1 reference

Europe PubMed Central

12 January 2018

http://europepmc.org/abstract/MED/15245599

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47220999&oldid=2146740187"